{
    "Clinical Trial ID": "NCT00934856",
    "Intervention": [
        "INTERVENTION 1: ",
        "  MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days)",
        "  Participants with HER2-positive MBC received docetaxel 75 mg/m^2 IV infusion on Day 1 and T-DM1 2.4 mg/kg IV infusion on Day 2 of Cycle 1 followed by T-DM1 75 mg/m^2 and docetaxel 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 75 mg/m^2 was stopped and T-DM1 2.4 mg/kg was continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.",
        "INTERVENTION 2: ",
        "  MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Over 2 Days)",
        "  Participants with HER2-positive MBC received docetaxel 60 mg/m^2 IV infusion on Day 1 and T-DM1 2.4 mg/kg IV infusion on Day 2 of Cycle 1 followed by T-DM1 60 mg/m^2 and docetaxel 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m^2 was stopped and T-DM1 2.4 mg/kg was continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (ECOG performance status of 2 will be allowed if only due to debilitating bone disease)",
        "  HER2-positive metastatic or locally advanced breast cancer",
        "  For MBC participants:",
        "  Documented metastatic or inoperable locally advanced (without meeting LABC criteria) disease, amenable for treatment with docetaxel",
        "  History of disease progression within 3 months prior to study entry",
        "  For LABC participants:",
        "  Newly diagnosed locally advanced breast cancer, Stage IIA-IIIC (American Joint Committee on Cancer [AJCC] staging system)",
        "Exclusion Criteria:",
        "  Significant cardiac disease",
        "  Inadequate bone marrow, liver or renal function",
        "  For MBC participants:",
        "  Participants must not have received radiotherapy for the treatment of metastatic or locally recurrent/advanced disease other than for the relief of pain in progressing metastatic bone lesions and/or brain metastases",
        "  Brain metastases that are untreated, symptomatic or require therapy to control symptoms; or any radiation, surgery, or other therapy to control symptoms from brain metastasis within 2 months of the first study treatment.",
        "  For LABC participants:",
        "  Clinically or radiologically detectable metastasis (M1 disease)",
        "  Participants for whom surgery as primary intent procedure is the best option to treat their disease",
        "  Participants must not have received any systemic or loco-regional anti-cancer therapy for the treatment of locally advanced disease"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants With Dose Limiting Toxicity (DLT) - MBC and LABC Feasibility Population",
        "  DLTs included (as per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] grading): Grade 4 thrombocytopenia, thrombocytopenia of any grade with concurrent hemorrhage or requiring blood platelet transfusion, or thrombocytopenia not recovered by Day 21 to at least 100,000/microliter (mcL); Grade 4 neutropenia lasting for more than 7 days; Febrile neutropenia; Grade greater than or equal to (>/=) 3 neurotoxicity in the form of peripheral neuropathy or peripheral neurotoxicity not improving to baseline or Grade less than or equal to (</=) 1 by Day 21; Any non-hematological toxicity of Grade >/= 3 except for alopecia, fever, and chills, not improving to baseline or Grade </=1 by Day 21, despite adequate toxicity management; Any subjective intolerable toxicity felt by the investigator to be related to either study treatment; Any other treatment-related toxicity prohibiting the start of the Cycle 2 on Day 22; Fulminant skin rash.",
        "  Time frame: Cycle 1 (up to 21 days)",
        "Results 1: ",
        "  Arm/Group Title: MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days)",
        "  Arm/Group Description: Participants with HER2-positive MBC received docetaxel 75 mg/m^2 IV infusion on Day 1 and T-DM1 2.4 mg/kg IV infusion on Day 2 of Cycle 1 followed by T-DM1 75 mg/m^2 and docetaxel 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 75 mg/m^2 was stopped and T-DM1 2.4 mg/kg was continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.",
        "  Overall Number of Participants Analyzed: 6",
        "  Measure Type: Number",
        "  Unit of Measure: participants  2",
        "Results 2: ",
        "  Arm/Group Title: MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Over 2 Days)",
        "  Arm/Group Description: Participants with HER2-positive MBC received docetaxel 60 mg/m^2 IV infusion on Day 1 and T-DM1 2.4 mg/kg IV infusion on Day 2 of Cycle 1 followed by T-DM1 60 mg/m^2 and docetaxel 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m^2 was stopped and T-DM1 2.4 mg/kg was continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.",
        "  Overall Number of Participants Analyzed: 6",
        "  Measure Type: Number",
        "  Unit of Measure: participants  1"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 2/6 (33.33%)",
        "  Febrile neutropenia * 1/6 (16.67%)",
        "  Neutropenia * 0/6 (0.00%)",
        "  Thrombocytopenia * 1/6 (16.67%)",
        "  Diarrhoea * 0/6 (0.00%)",
        "  Pyrexia * 0/6 (0.00%)",
        "  Thrombosis in device * 1/6 (16.67%)",
        "  Fatigue * 0/6 (0.00%)",
        "  Mucosal inflammation * 0/6 (0.00%)",
        "  Device deployment issue * 0/6 (0.00%)",
        "  Hepatocellular injury * 1/6 (16.67%)",
        "  Cholecystitis * 1/6 (16.67%)",
        "Adverse Events 2:",
        "  Total: 2/6 (33.33%)",
        "  Febrile neutropenia * 1/6 (16.67%)",
        "  Neutropenia * 1/6 (16.67%)",
        "  Thrombocytopenia * 0/6 (0.00%)",
        "  Diarrhoea * 0/6 (0.00%)",
        "  Pyrexia * 0/6 (0.00%)",
        "  Thrombosis in device * 1/6 (16.67%)",
        "  Fatigue * 0/6 (0.00%)",
        "  Mucosal inflammation * 0/6 (0.00%)",
        "  Device deployment issue * 0/6 (0.00%)",
        "  Hepatocellular injury * 0/6 (0.00%)",
        "  Cholecystitis * 0/6 (0.00%)"
    ]
}